Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (13058)	3/8/1999 10:07:00 AM
From: Rock_nj	Read Replies (1) \| Respond to of 25711

IVCO is on the move. They hired KCSA to do their PR. KCSA is big in Internet promotion. Speculation is that IVCO is going to open a website.

To: Joe Copia who wrote (13058)	3/8/1999 10:10:00 AM
From: T2001	Respond to of 25711

Angeion Receives Approval to Market Lyra(TM) 2020 ICD and AngePass 4040 Lead Systems; Approval Triggers $10 Million Equity Investment MINNEAPOLIS, March 8 /PRNewswire/ -- Angeion Corporation (Nasdaq: ANGN) announced today that is has received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the U.S. market release of its Lyra(TM) 2020 Series of implantable cardioverter defibrillators (ICD), and its AngePass(TM) 4040 and 4080 lead systems. The PMA triggers a $10 million equity investment from Angeion's marketing partner, Synthelabo, $5 million for the approval of the Lyra and $5 million for the approval of the AngePass leads. "With receipt of the PMA for our 2020 ICD Series and AngePass leads -- and the equity investment, we continue to make significant progress," said Jim Hickey, Angeion's President and CEO. "We are pleased to be able to introduce this product to the U.S. marketplace, which represents approximately 80 percent of the more than $1 billion worldwide market." The Lyra 2020 Series of ICDs is designed to provide value to the patient and physician in terms of patient comfort, reduced trauma and ease of implant. The 2020 represents one of the smallest ICDs implanted to date with a volume of only 47 cc and weight of 88 grams. Offering an elongated, rounded-edge shape to accommodate a smaller incision, the Lyra is designed to improve implantation and long-term patient comfort. With a projected device longevity of 8-9 years and diagnostic capabilities of one full hour of programmable stored electrograms for later retrieval and analysis, the Lyra Series is Angeion's most advanced product to date in its pipeline of arrhythmia products. Angeion Corporation designs, develops and manufactures ICD systems for the tachyarrhythmia (rapid irregular heartbeats) market. Angeion's internet address is: angeion.com. The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements by their nature involve substantial risks and uncertainties. Actual results may differ materially depending on a variety of factors, including, but not limited to, the following: need to obtain additional capital; progress with clinical trials; time and costs involved in obtaining regulatory approvals; costs involved in filing, prosecuting and enforcing patents and defending against patent infringement claims; competing technological and market developments; costs of manufacturing and marketing scale-up; funding needs of the joint venture; and success of the strategic alliance with Synthelabo. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the prior discussion is qualified in its entirety by, the Risk Factors contained in the Company's Current Report of Form 8-K, as filed with the SEC on April 20, 1998, and the Company's other periodic filings with SEC, copies of which are available upon request. SOURCE Angeion Corporation /CONTACT: Jim Hickey, President & CEO, or Jill Burchill, CFO, both of Angeion, 612-315-2000/ /Web site: angeion.com (ANGN)